Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments (2018 - 2026)

Allogene Therapeutics has disclosed Change in Acquisitions & Divestments across 9 years of filings, most recently posting $72.1 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $72.1 million, up 27.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $249.8 million (up 703.8% YoY), and the FY2025 annual result was $234.2 million, up 4238.68% from the prior year.
• Change in Acquisitions & Divestments came in at $72.1 million for Q1 2026 at Allogene Therapeutics, up from $62.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $152.9 million in Q2 2023 to a low of -$324.9 million in Q4 2024.
• The 5-year median for Change in Acquisitions & Divestments is $65.3 million (2022), against an average of $22.7 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 131.82% in 2022 and surged 322.58% in 2023, its largest moves.
• Allogene Therapeutics' Change in Acquisitions & Divestments stood at -$68.7 million in 2022, then tumbled by 323.25% to -$290.7 million in 2023, then declined by 11.77% to -$324.9 million in 2024, then jumped by 119.08% to $62.0 million in 2025, then increased by 16.33% to $72.1 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $72.1 million (Q1 2026), $62.0 million (Q4 2025), and $61.9 million (Q3 2025), per Business Quant data.